SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:oru-88483"
 

Search: onr:"swepub:oai:DiVA.org:oru-88483" > Prevalence of adver...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Korjagina, MartaStatFinn-EPID Research, Tallinn, Estonia (author)

Prevalence of adverse pregnancy outcomes after exposure to interferon beta prior to or during pregnancy in women with MS : Stratification by maternal and newborn characteristics in a register-based cohort study in Finland and Sweden

  • Article/chapterEnglish2020

Publisher, publication year, extent ...

  • Elsevier,2020
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:oru-88483
  • https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-88483URI
  • https://doi.org/10.1016/j.msard.2020.102694DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:146763965URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Funding Agencies:Bayer AG Biogen Merck KGaA  Novartis Europharm Limited
  • BACKGROUND: Previous studies reported no increase in the prevalence of adverse pregnancy outcomes after exposure to interferon-beta (IFN-beta). However, no study has investigated if the prevalence of these outcomes after IFN-beta exposure is modified by maternal and newborn characteristics. Our objective was to describe the stratified prevalence of adverse pregnancy outcomes among women with multiple sclerosis (MS) exposed only to IFN-beta or unexposed to any MS disease modifying drugs (MSDMDs).METHODS: This population-based cohort study using Finnish (1996-2014) and Swedish (2005-2014) register data included pregnancies of women with MS exposed only to IFN-beta 6 months before or during pregnancy (n=718) or unexposed to MSDMDs (n=1397). The outcome prevalences were described stratified by maternal and newborn characteristics, with 95% confidence intervals (CIs). Confounder-adjusted analyses were performed if the prevalence results indicated modified effect of IFN-beta in specific strata.RESULTS: The stratified analysis indicated that the prevalence of serious (anomaly or stillbirth) and other adverse pregnancy outcomes was similar among the exposed and unexposed, with no statistically significant difference. Among women treated for MS >5 years, serious adverse pregnancy outcomes occurred in 4.3% (95%CI: 1.9-8.3%) of pregnancies exposed only to IFN-beta 6 months before or during pregnancy and in 2.7% (95%CI: 1.2-5.0%) of unexposed pregnancies. The confounder adjusted analyses did not support the hypothesis that MS treatment duration before pregnancy would modify the risk of adverse pregnancy outcomes after exposure to IFN-beta 6 months before or during pregnancy.CONCLUSION: The prevalence of adverse pregnancy outcomes was not increased after IFN-beta exposure, when pregnancies of women with MS were stratified by maternal and newborn characteristics. The stratified results were similar to the unstratified results in the same population.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Hakkarainen, Katja M.StatFinn-EPID Research, Mölndal, Sweden (author)
  • Burkill, SarahKarolinska Institute, Solna, Sweden (author)
  • Geissbühler, YvonneNovartis Pharma AG, Evidence and Launch Excellence, Basel, Switzerland (author)
  • Sabidó, MeritxellMerck KGaA, Darmstadt, Germany (author)
  • Everage, NicholasBiogen, Cambridge, MA, United States (author)
  • Suzart-Woischnik, KilianaBayer AG, Berlin, Germany (author)
  • Klement, RihoStatFinn-EPID Research, Tartu, Estonia (author)
  • Hillert, JanKarolinska Institutet (author)
  • Verkkoniemi-Ahola, AuliClinical Neurosciences, Neurology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland (author)
  • Bahmanyar, ShahramCentre for Pharmacoepidemiology, Department of Medicine, Karolinska Institutet, Solna, Sweden; Centre for Psychiatry Research, Karolinska Institutet, Norra Stationsgatan 69, floor 7, 113 64 Stockholm, Sweden; Stockholm Health Care Services, Stockholm, Sweden (author)
  • Montgomery, Scott,1961-Karolinska Institutet,Örebro universitet,Institutionen för medicinska vetenskaper,Clinical Epidemiology Division, Department of Medicine, Karolinska Institute, Solna, Sweden; Örebro University Hospital, Örebro, Sweden; Department of Epidemiology and Public Health, University College London, London, United Kingdom,Clinical Epidemiology and Biostatistics(Swepub:oru)smy (author)
  • Korhonen, PasiStatFinn-EPID Research, Espoo, Finland (author)
  • StatFinn-EPID Research, Tallinn, EstoniaStatFinn-EPID Research, Mölndal, Sweden (creator_code:org_t)

Related titles

  • In:Multiple Sclerosis and Related Disorders: Elsevier482211-03482211-0356

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view